An easily adaptable validated risk score predicts cancer-specific survival in stage II colon cancer

Figures & data

Table 1. Demographics of the stage II colon cancer study populations.

	Training cohort	Validation cohort
Number of patients	704	183
Female	352 (50%)	86 (47%)
Median and mean age (range)	74 and 72 (26–96) years	69 and 69 (35–93) years
Comorbidities present^a
0	63%	61%
1	25%	26%
2 or more	12%	13%
Right-sided primary	346 (49%)	101 (55%)
Known microsatellite stability	80	Not available
Adjuvant therapy for at least 3 months	102 out of 485 patients (21%)^b	57 (30%)
High-risk factors
T4	99/704 (14%)	76/183 (41%)
Gradus 3	75/689 (11%)	30/149 (20%)
LVI/PNI	88/428 (21%)	101/160 (63%)
<12 lymph nodes dissected	239/703 (35%)	7/153 (5%)
Obstruction/perforation	120/704 (17%)	14/183 (8%)
R1 resection (≤1mm)	7/704 (1%)	4/183 (2%)

^aAccording to Charlson comorbidity classification.

^bSatakunta adjuvant chemotherapy data was not available.

Figure 1. Ten-year cancer-specific survival according to the risk score (RS). (A) Training cohort of 704 patients. (B) Validation cohort of 183 patients. (C) Prediction accuracy of the training and validation cohorts. (D) For comparison, traditional practice using the training cohort, where the number of high-risk factors are added together.